Description

Apellis Crashed, Stalled, Then Exploded 136% Overnight—Here’s Why!

Apellis Pharmaceuticals did not become a different business the moment Biogen agreed to buy it for about $5.6 billion. What changed was the market’s frame of reference. For months, investors had treated the company like a damaged biotech story: Syfovre growth looked soft, competitive pressure was building, and sentiment across smaller biotech names was weak. Then Biogen agreed to pay $41 per share, plus contingent value rights tied to Syfovre sales targets, and the stock jumped toward that value. That move looked dramatic, but it was really a repricing event. The same company that had been marked down as disappointing one day was suddenly treated as a strategic asset the next. That disconnect is what makes the story interesting. The business still had two commercial drugs, a meaningful revenue base, and several pipeline programs that could matter inside a larger portfolio. The market focused on near-term frustration.